Eton Pharmaceuticals (NASDAQ:ETON) Price Target Increased to $11.00 by Analysts at HC Wainwright

Eton Pharmaceuticals (NASDAQ:ETON) had its price target boosted by analysts at HC Wainwright from $9.00 to $11.00 in a report issued on Friday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s target price indicates a potential upside of 57.14% from the stock’s current price. HC Wainwright also issued estimates for Eton Pharmaceuticals’ Q4 2024 earnings at ($0.01) EPS, Q1 2025 earnings at $0.12 EPS, Q2 2025 earnings at $0.13 EPS, Q3 2025 earnings at $0.16 EPS and Q4 2025 earnings at $0.18 EPS.

Eton Pharmaceuticals Stock Up 1.3 %

ETON stock opened at $7.00 on Friday. The company’s 50-day moving average price is $4.71 and its two-hundred day moving average price is $3.92. The firm has a market cap of $179.84 million, a P/E ratio of 175.00 and a beta of 1.31. Eton Pharmaceuticals has a 12 month low of $3.03 and a 12 month high of $7.07.

Eton Pharmaceuticals (NASDAQ:ETON) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.05). Eton Pharmaceuticals had a negative return on equity of 43.62% and a negative net margin of 21.31%. The firm had revenue of $9.07 million for the quarter, compared to analyst estimates of $10.00 million. Equities analysts predict that Eton Pharmaceuticals will post -0.15 EPS for the current year.

Insider Transactions at Eton Pharmaceuticals

In other Eton Pharmaceuticals news, major shareholder Opaleye Management Inc. acquired 57,500 shares of Eton Pharmaceuticals stock in a transaction that occurred on Tuesday, September 10th. The shares were acquired at an average cost of $4.65 per share, with a total value of $267,375.00. Following the completion of the purchase, the insider now directly owns 2,660,000 shares of the company’s stock, valued at $12,369,000. This represents a 0.00 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 14.89% of the stock is owned by insiders.

Hedge Funds Weigh In On Eton Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in ETON. Nantahala Capital Management LLC bought a new stake in shares of Eton Pharmaceuticals during the second quarter worth $3,095,000. Aristides Capital LLC bought a new stake in Eton Pharmaceuticals during the 2nd quarter worth $658,000. Thompson Siegel & Walmsley LLC acquired a new position in Eton Pharmaceuticals in the 2nd quarter worth about $420,000. Stonepine Capital Management LLC acquired a new position in Eton Pharmaceuticals in the 2nd quarter worth about $362,000. Finally, Opaleye Management Inc. raised its position in Eton Pharmaceuticals by 4.1% in the fourth quarter. Opaleye Management Inc. now owns 2,529,887 shares of the company’s stock valued at $11,081,000 after purchasing an additional 99,617 shares during the last quarter. Institutional investors own 27.86% of the company’s stock.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.